Best Saccharomyces Boulardii for IBS Symptom Management (2026)

S. boulardii is a transient yeast — it doesn't permanently colonize the gut, but exerts effects while passing through. Several mechanisms have been proposed based on human and mechanistic research. It appears to modulate intestinal immune responses, with Abbas et al. (2014) documenting changes in pro-inflammatory cytokine levels in IBS-D patients alongside clinical improvements. It may also interfere with pathogen adhesion to intestinal epithelial cells and produce proteases that degrade bacterial toxins. The 2023 Bustos Fernández pilot study adds another layer: in IBS-D patients, CNCM I-745 supplementation was associated with reductions in small intestinal bacterial overgrowth markers and shifts in microbiota composition. This is clinically interesting because SIBO is a proposed contributing factor in a subset of IBS-D cases. S. boulardii doesn't act like a standard probiotic that you're trying to permanently establish — think of it more as a temporary modulator that influences the gut environment during transit. This also explains why some clinicians recommend it in defined courses rather than indefinite daily use.

The first decision is whether you specifically need S. boulardii or whether you're open to the best-evidenced probiotic for IBS broadly. These aren't the same answer. If you're about to take antibiotics, recently finished a course, or your GI doctor suspects SIBO as a contributing factor, S. boulardii's yeast identity gives it a practical advantage no bacterial strain can match. But if your goal is purely IBS symptom reduction without those specific circumstances, the evidence for B. infantis 35624 is arguably stronger. If you've decided S. boulardii is right for you, strain identity is the next non-negotiable. The CNCM I-745 designation is what distinguishes Florastor from generic S. boulardii products — most of the meaningful IBS clinical trial data, including the 2023 microbiota study and the quality-of-life RCT data, used this specific strain. That doesn't mean other strains do nothing, but it means the evidence doesn't transfer cleanly. This is the supplement equivalent of brand-name versus generic for a drug where bioequivalence hasn't been formally established. Dosage and delivery format both matter. S. boulardii products vary between 250 mg per capsule (as in Florastor) and higher CFU single-capsule products like Jarrow's 5 billion CFU format. 'CFU equivalent' language used by Florastor reflects a lyophilized form — the 5 billion CFU equivalent is actually delivered via a 250 mg lyophilized powder per capsule, which is the form used in most clinical research. Single-capsule convenience may favor adherence for some users, while Florastor's two-capsule serving delivers the research-matched dose across two pills. Finally, think realistically about cost over time. IBS is chronic. A product that costs $0.90/day sounds manageable until you're 18 months in and have spent over $450 on a supplement with moderate evidence. Jarrow's $0.33/day format addresses this directly — if the strain caveat is acceptable to you after discussing it with your provider, the sustainability argument is real.